Press Releases Landos Biopharma, Inc.

Equities

LABP

US5150692011

Real-time Estimate Cboe BZX Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
22.4 ^USD	-0.31%		+0.02%	+506.83%

May. 09	Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	North American Morning Briefing : Stocks Seen -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP	May. 11	BU
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie	Apr. 16	PR
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP	Mar. 27	BU
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP	Mar. 26	PR
INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE	Mar. 25	PR
Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie	Mar. 25	PR
LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders	Mar. 25	BU
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases	Mar. 25	PR
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases	Mar. 25	AQ
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results	Mar. 21	AQ
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation	Jan. 08	AQ
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis	Nov. 21	AQ
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results	Nov. 09	AQ
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	Nov. 09	AQ
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting	23-10-23	AQ
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress	23-09-19	AQ
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells	23-09-14	AQ
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results	23-08-09	AQ
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference	23-05-31	AQ
LANDOS BIOPHARMA, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-05-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Landos Biopharma, Inc.

Equities

LABP

US5150692011

Press Releases

Filters